Perrigo Co. (NYSE: PRGO) announced that its board of directors declared a quarterly dividend of 9 cents per share.
The Allegan generic drug maker will begin making two oils for dermatitis and a cancer drug.
The health and beauty products maker Perrigo Co. (NYSE: PRGO) announced that its infant formula division, Perrigo Nutritionals, is working with the American Academy of Pediatrics to increase educational awareness around infant nutrition, health, and feeding options.
The Allegan generic and store-brand health products maker Perrigo Co. announced early Monday that it would acquire Dublin, Ireland-based Elan Corp. plc for $8.6 billion (5.6 billion pounds).
Perrigo Co. (Nasdaq: PRGO) announced that it has received tentative approval from the United States Food & Drug Administration for its abbreviated new drug application for repaglinide tablets, the generic equivalent to Prandin Tablets.
The Allegan-based generic and store-brand health products manufacturer Perrigo Co. said Monday it had purchased the ophthalmic sterile ointment and solution porfolio of Fera Pharmaceuticals LLC and its affiliates of Long Island, N.Y.
Perrigo Co. (Nasdaq: PRGO) announced that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for testosterone topical solution, the generic version of Axiron Topical Solution.
Perrigo Co. (Nasdaq: PRGO) Thursday announced that it is transferring the listing of its U.S. traded common stock to the New York Stock Exchange from the Nasdaq Global Select Market.
Perrigo Co. announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter medications sold at leading retailers — also known as “store brand” OTCs.
The generic drug and store brand health products maker Perrigo Co. (Nasdaq: PRGO) Wednesday reported record revenue of $919.8 million in the third fiscal quarer ended March 30, up from $778 million a year earlier.